# Abpro

**Canonical:** https://apis.io/providers/abpro/  
**Website:** https://abpro.co/  
**APIs profiled:** 0

Abpro Holdings, Inc. is a clinical-stage biotechnology company headquartered in the Boston area (Woburn / Burlington, Massachusetts) that develops next-generation multispecific antibody therapeutics for oncology and ophthalmology. Its DiversImmune antibody-discovery platform and MultiMab multispecific-engineering platform are used to build bispecific and tetravalent T-cell-engager constructs, led by ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager partnered with Celltrion, alongside the ABP-110, ABP-150 and ABP-201 programs. Abpro is a drug developer rather than a software company: its public web surface is a corporate and investor-relations site, and it publishes no developer program, public API, SDK, webhook surface, or machine-readable specification of any kind.

## Kin Score — 7.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 7.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 12.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Abpro Domain Security** — TLSv1.3

## Tags

Company, Biotechnology, Pharmaceuticals, Antibody Therapeutics, Oncology, Life Sciences, Drug Discovery, Clinical Stage

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/abpro/). Scores are computed from the provider's own public artifacts under a published rubric.